

Shedding of Infectious SARS-CoV-2 Despite Vaccination

Kasen K. Riemersma, DVM, PhD¹; Luis A. Haddock III, MS¹; Nancy A. Wilson, PhD²; Nicholas Minor, BS²; Jens Eickhoff, PhD³; Brittany E. Grogan, MPH⁴; Amanda Kita-Yarbro, MPH⁴; Peter J. Halfmann, PhD¹; Hannah E. Segaloff, PhD⁵; Anna Kocharian, MS⁶; Kelsey R. Florek, MPH, PhD⁷; Ryan Westergaard, MD, PhD⁸; Allen Bateman, PhD⁷; Gunnar E. Jeppson, BS⁹; Yoshihiro Kawaoka, DVM, PhD¹; David H. O'Connor, PhD²; Thomas C. Friedrich, PhD¹; Katarina M. Grande, MPH⁴

¹Department of Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI, USA

²Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

³Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

⁴Public Health Madison & Dane County, Madison, WI, USA

⁵Epidemic Intelligence Service, CDC, Atlanta, GA, USA

⁶Wisconsin Department of Health Services, Madison, WI, USA

⁷Wisconsin State Laboratory of Hygiene, Madison, WI, USA

⁸Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

⁹Exact Sciences, Madison, WI, USA

[^]These authors contributed equally.

Correspondence can be addressed to:

Katarina Grande, KGrande@publichealthmdc.com

Short title: SARS-CoV-2 RNA levels in breakthrough and unvaccinated Delta infections

Abstract

The SARS-CoV-2 Delta Variant of Concern is highly transmissible and contains mutations that confer partial immune escape. The emergence of Delta in North America caused the first surge in COVID-19 cases after SARS-CoV-2 vaccines became widely available. To determine whether individuals infected despite vaccination might be capable of transmitting SARS-CoV-2, we compared RT-PCR cycle threshold (Ct) data from 20,431 test-positive anterior nasal swab specimens from fully vaccinated (n = 9,347) or unvaccinated (n=11,084) individuals tested at a single commercial laboratory during the interval 28 June – 1 December 2021 when Delta variants were predominant. We observed no significant effect of vaccine status alone on Ct value, nor when controlling for vaccine product or sex. Testing a subset of low-Ct (<25) samples, we detected infectious virus at similar rates, and at similar titers, in specimens from vaccinated and unvaccinated individuals. These data indicate that vaccinated individuals infected with Delta variants are capable of shedding infectious SARS-CoV-2 and could play a role in spreading COVID-19.

Main text

Introduction

The SARS-CoV-2 Delta variant was initially characterized in March 2021 and was associated with increased infection incidence in North America beginning in the summer of 2021. In Wisconsin, Delta-lineage viruses were first detected on 12 April 2021, and within 10 weeks accounted for more than 90% of sequenced viruses. Delta viruses were highly transmissible and contained mutations that confer partial immune escape. The “surge” in cases attributable to Delta-lineage viruses represented the first substantial increase in SARS-CoV-2 infection incidence after vaccines had become widely available in the United States. By July 2021, SARS-CoV-2 infection incidence was low in the United States (<https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/past-reports/05212021.html#print>) [1], and national and local public health agencies were loosening requirements for face coverings and other non-pharmaceutical interventions to reduce virus transmission [1–3]. A key question in developing these policies was whether persons infected with SARS-CoV-2 despite vaccination could transmit infection to others.

By late July 2021, outbreak investigations suggested that vaccinated persons who became infected could spread Delta-lineage SARS-CoV-2 [4,5]. To determine whether individuals with vaccine breakthrough infections could shed Delta viruses at levels consistent with potential transmission, we compared the SARS-CoV-2 RNA burden in nasal swab specimens from vaccinated and unvaccinated individuals tested at a single commercial laboratory. We also attempted virus isolation and determined infectious viral titers from a subset of samples from vaccinated and unvaccinated individuals. We focus here on samples collected between 28 June 2021 and 1 December 2021, an interval that spans the time when Delta virus first accounted for at least 90% of sequenced specimens in Wisconsin and the first detection of an Omicron sequence on 4 December 2021 (<https://www.dhs.wisconsin.gov/news/releases/120421.htm>).

Methods

Study design

To estimate nasal viral RNA burden, we compared RT-PCR cycle threshold (Ct) data from 30,101 test-positive anterior nasal swab specimens from fully vaccinated (n = 9,347) or unvaccinated (n = 11,084) individuals. Samples were collected using the same collection kits from multiple clinic locations. All viral RNA extraction and RT-PCR was performed at a single commercial testing provider (Exact Sciences, Madison, WI) using the same protocol. Because this is a cross-sectional study analyzing specimens submitted for clinical testing, we are only able to analyze a single timepoint from most individuals in our cohort. The estimated prevalence of Delta in Wisconsin was 60% at the start of the study on 28 June 2021, reached 95% by 23 July 2021, and remained at or above 95% until 12 December, 2021 (outbreak.info). The cutoff date was chosen to exclude samples containing the Omicron variant, which was first detected in Wisconsin 4 December 2021.

RT-PCR assay

The Flu-SC2 Multiplex Assay (<https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html>) as implemented by Exact Sciences was used to determine Ct values. This RT-PCR assay can simultaneously detect nucleic acid from SARS-CoV-2, as well as Influenza A and B from anterior nasal swabs. RNA extraction was conducted using Exact Sciences Corporation's proprietary extraction procedure on the Hamilton STARlet liquid handler. The oligonucleotide primers and probe for detection of SARS-CoV-2 were selected from an evolutionarily conserved region of the 3' terminus of SARS-CoV-2 genome and also cover part of the 3'-terminal portion of the nucleocapsid (N) gene. RNA isolated from anterior nasal swab specimens was reverse transcribed into cDNA and amplified using the ThermoFisher TaqPath 1-Step RT-qPCR Master Mix and Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument with SDS version 1.4.1 software. Controls included a no-template control, a positive extraction control containing human RNase P, and an internal control for RNase P.

Defining vaccination status

Individuals were considered fully vaccinated at the time of testing if vaccine registry or self-reported data indicated receiving a final vaccine dose at least 14 days prior to submitting the specimen that tested positive for SARS-CoV-2 and was used in our analysis. We used validated public health vaccine registries for the State of Wisconsin where possible. Self-reported vaccination status was included with sample metadata submitted by testing providers to the Exact Sciences laboratory; when individuals' vaccination status was not available in public health databases, we used self-report data to determine status. Comparing self-reporting to data from vaccine registries determined that under-reporting of full vaccination status was more common than over-reporting (**Supplemental Figure 1**).

Specimens from individuals who were partially vaccinated (i.e., had not received a complete vaccine series, were tested <14 days after the final dose, or those whose vaccination dates were after the sample collection date) were excluded. We also excluded 430 samples from individuals who received a booster vaccine dose prior to the sample collection date, since these individuals represented a small fraction of the total number of available samples and booster effects could confound our analyses.

Virus isolation and plaque assay

With an initial set of specimens with Ct values <25, we assessed the presence of infectious virus by inoculating residual specimens onto a monolayer of Vero E6/TMPRSS2 cells and monitoring for the presence of cytopathic effects over 5 days. Specimens were selected by N1 Ct-matching between fully vaccinated and unvaccinated persons. Specimens from individuals with unknown vaccine status were excluded from this assay. With a second set of samples, we determined virus titer, expressed as plaque-forming units (PFU) per ml specimen, by using a 10-fold dilution series along with undiluted samples to infect a monolayer of Vero E6/TMPRSS2 cells (100 µl per well) for 30 minutes at 37°C. The cells were washed once to remove unbound virus, then overlaid with 1% methylcellulose for four days at which time plaques were counted.

Statistical analysis

We used analysis of variance (ANOVA) to evaluate how Ct values varied between age groups, sexes, and by

vaccine product, as well as two-way interactions between these factors. Raw Ct values were not normally distributed, so we log-transformed all Ct values prior to ANOVA, and confirmed normality by plotting residuals and normal probability (**Supplemental Figure 2**). We report least square means along with the corresponding 95% confidence intervals (CIs). Tukey's Honestly Significant Difference Method (HSD) was used to control the type I error when conducting multiple comparisons between groups. Because our dataset included individuals with varying amounts of time between vaccination and SARS-CoV-2 infection, it is possible that waning levels of immunity could impact susceptibility to infection and/or viral loads after vaccination. To determine whether there was a relationship between time since vaccination and Ct values in infected persons, we conducted additional regression analyses that included months since completion of vaccination as a vaccine manufacturer-specific continuous predictor variable. Months since completion of vaccination was defined as the number of days since completion divided by 30.44, the average number of days per month.

In order to quantify and interpret differences between groups, we calculated standardized differences (Cohen's effect size d), defined as the mean differences between groups divided by the pooled standard deviations. Effect sizes of $d < 0.2$ were considered to indicate either no difference or a negligible difference between populations. An effect size of 0.2 to 0.5 indicated a small difference, 0.5 to 0.8 was a moderate difference, and > 0.8 was a large difference. The proportions of subjects with Ct values < 25 were compared between groups using a chi-square test.

The results of the primary comparisons were confirmed by conducting nonparametric analyses. Specifically, the nonparametric Wilcoxon rank sum test was used to conduct comparisons between Ct values between the two groups, and the nonparametric Kruskal-Wallis test was used to conduct the comparisons of Ct values between more than two groups. Statistical analyses were conducted using SAS software (SAS Institute, Cary NC), version 9.4, figures were plotted using the R package ggplot2 [6] or from Prism version 9.3.1.

Results

Individuals infected with SARS-CoV-2 despite vaccination have low Ct values.

SARS-CoV-2 RT-PCR Ct values <25 had previously been associated with shedding of infectious SARS-CoV-2 [7,8]. We observed Ct values <25 in 6,253 of 9,347 fully vaccinated (67%) and 6,739 of 11,084 (61%) unvaccinated individuals (**Figure 1A**). Because of the very large number of samples, very small differences in outcome variables may nonetheless reach statistical significance when using p values with a traditional alpha set to 0.05. That is, we may find small differences between groups that are statistically significant ($p < 0.05$), but have a negligible effect ($d < 0.2$). In order to quantify the magnitude of differences between groups, we calculated standardized differences (Cohen's effect size d), defined as the mean differences between the groups divided by the pooled standard deviations. A value of $d < 0.2$ indicates negligible effects of the analyzed variables on the outcome variable. Here we report values for both p and d for completeness. We observed no significant effect of vaccination status on Ct values in infected persons (Cohen's $d=0.14$, $p<0.0001$; **Table 1**). Low Ct values were detected in vaccinated people whether or not they reported symptoms at the time of testing (**Figure 1B**), with Ct values <25 detected in 65% (95% CI:63-66%) of unvaccinated symptomatic individuals and in 70% (95% CI:69-71%) of fully vaccinated symptomatic individuals ($p<0.0001$). Notably, for symptomatic individuals, time from symptom onset to testing did not vary by vaccination status. Both vaccinated and unvaccinated individuals in our population reported a median time of 2.4 days between symptom onset and testing. 92% of individuals in our dataset sought testing within 6 days of symptom onset. Together these results suggest that our observations are not confounded by biases in test-seeking behavior between vaccinated and unvaccinated persons (Two-sided K-S test: $p=0.0012$; medians 2.40d unvaccinated, 2.42d vaccinated, **Supplemental Figure 3**).

Table 1: *Vaccinated vs. Unvaccinated*

	Means	95% CI	Effect size d	p-value
Unvaccinated (N=11,084)	22.9	22.8-23.0	0.14	<0.0001
Vaccinated (N=9,347)	22.1	22.0-23.2		

Interpretation of effect size d : ($d<0.2$ no difference/negligible difference, 0.2-0.5 small difference, 0.5-0.8 moderate difference, >0.8 large difference)

Individuals infected with SARS-CoV-2 despite vaccination shed infectious virus.

Previous studies focusing primarily on unvaccinated individuals suggested that RT-qPCR Ct values <25 may be strongly associated with the shedding of infectious SARS-CoV-2 [8,9]. To determine whether vaccinated persons with potentially high viral burdens might be capable of shedding infectious virus, we inoculated a subset of residual specimens with Ct values <25 onto a monolayer of Vero E6/TMPRSS2 cells and monitored for the presence of cytopathic effects over 5 days. Specimens were selected by N1 Ct-matching between fully vaccinated and unvaccinated persons. Specimens from individuals with unknown vaccine status were excluded from this assay. 37 of 39 specimens from vaccinated individuals contained culturable SARS-CoV-2, as compared with 15 of 17 specimens from unvaccinated persons (**Supplemental Figure 4**). We therefore performed virus titration on a

second set of samples with Ct < 25 and found no difference in infectious virus titer between samples from vaccinated vs. unvaccinated individuals (**Figure 1C**).

Ct value in breakthrough infection is not strongly affected by vaccine product, age, or sex.

We considered whether different vaccine products affected Ct values observed in individuals with breakthrough infections. Vaccination had negligible effects on mean Cts in vaccinated as compared with unvaccinated individuals, regardless of the manufacturer, (Janssen (JNJ-78436735) effect size $d=0.18$, $p<0.0001$; Moderna (mRNA-1273) effect size $d=0.07$, $p=0.0052$; Pfizer (BNT162b2) effect size $d=0.17$, $p<0.0001$; **Supplemental Figure 5A**; see also **Supplemental Table 1**). Low-Ct samples were found in similar proportions among all groups, Janssen 68% Ct<25, Moderna 64% Ct<25 and Pfizer 68% Ct<25.

Vaccine effectiveness, particularly against symptomatic, test-positive SARS-CoV-2 infection, wanes with time after vaccine receipt [10–21]. We therefore asked whether Ct values decreased as a function of time between last vaccination and the time at which individuals tested positive for SARS-CoV-2 infection. Indeed, when considering all vaccine products combined, there was a small, but statistically significant decrease in Ct values (consistent with higher levels of SARS-CoV-2 RNA in swab specimens) as the time between last vaccination and positive test increased (Slope: -0.18 , 95% CI: $-0.26 - 0.10$; $p\text{-value}<0.0001$; **Supplemental Figure 5B**). However, when we stratify individuals according to vaccine product received, we find that this effect seems to be driven principally by high Ct values among Pfizer vaccine recipients infected in the first month after vaccination, as the slopes of Ct value vs time between vaccination and infection are not significantly different from zero for recipients of the other two products (**Supplemental Figure 5B**).

Age and male sex have been considered risk factors for COVID-19 disease [22–26]. While one might hypothesize that older individuals and/or males might have higher SARS-CoV-2 burdens and therefore lower Ct values at the time of testing, evidence for this is mixed, with some studies reporting lower Ct values in older individuals [24,27], others in younger individuals [28], and still others finding no difference by age [20,29–34]. We therefore stratified groups based on age and compared Ct values by age group. Vaccination status had negligible effects on Ct values ($d<0.2$) for all age groups considered except those aged 0–11 years (**Supplemental Table 2**). In this group, there were very few vaccinated individuals ($N=7$), as would be expected because vaccines had not been approved for those 11 and under for most of our study period. Therefore, despite the significant effect size ($d=0.79$, $p=0.0466$), we do not believe our data strongly support the notion that vaccination status has a strong effect on Ct value in children under 12. When comparing Ct values between unvaccinated and vaccinated within males and females, negligible differences were observed (female: $d=0.14$, male: $d=0.15$; **Supplemental Table 3**).

212 Discussion

213 The emergence of Delta variants in the United States led to the first wave of increasing case burdens following
 214 the widespread availability of SARS-CoV-2 vaccines. At the time, prevailing public health recommendations were
 215 that vaccinated persons need not use face coverings in indoor settings. These recommendations were based in
 216 part on the fact that vaccines demonstrated remarkable effectiveness against test-positive SARS-CoV-2 infec-
 217 tion in initial clinical trials conducted in 2020 [35–40], suggesting that vaccinated persons might play negligible
 218 roles in SARS-CoV-2 transmission. However, the initial vaccine effectiveness studies were conducted when
 219 ancestral variants predominated, prior to the emergence of variants of concern. Here we conducted a compre-
 220 hensive retrospective analysis of RT-PCR Ct values in persons infected with SARS-CoV-2 during the time when
 221 Delta variants predominated, to determine whether individuals infected with Delta variants despite vaccination
 222 could be involved in community spread of SARS-CoV-2. Combined with other studies [41,42] our data indicate
 223 that vaccinated as well as unvaccinated individuals infected with SARS-CoV-2 Delta variants can shed, and po-
 224 tentially transmit, infectious virus [43,44]. We find low Ct values in substantial proportions of both unvaccinated
 225 and vaccinated individuals who tested positive for SARS-CoV-2 during the time when Delta variants predominat-
 226 ed, in agreement with other recent reports [41,44–47]. The occurrence in our dataset of positive samples from
 227 multiple Wisconsin counties without a linking outbreak (more than 80% of samples were not associated with an
 228 outbreak known to public health) indicate that Delta-lineage SARS-CoV-2 can achieve low Ct values consistent
 229 with transmissibility in fully vaccinated individuals across a range of environments. Importantly, we also show that
 230 infectious SARS-CoV-2 is found at similar titers in vaccinated and unvaccinated persons.

231
 232 An important limitation of our study is that we analyzed only single specimens from each infected individual, so
 233 our data cannot determine whether vaccinated individuals control virus replication in the upper respiratory tract
 234 more quickly than unvaccinated persons, as other studies have suggested [42]. We also note that the duration
 235 and level of infectious virus shedding varies widely among individuals [48], and that Ct values are an imperfect
 236 proxy for shedding of infectious virus. However, the vast majority of individuals included in our study were tested
 237 within 6 days of symptom onset (**Supplemental Figure 3**), a time before viral loads diverged in vaccinated and
 238 unvaccinated persons tested daily in a previous study [42]. Our cross-sectional, laboratory-based study was also
 239 not designed to detect or quantify differences in the relative roles of vaccinated and unvaccinated persons in
 240 spreading SARS-CoV-2 in the community.

241
 242 We find that a substantial proportion of individuals infected with Delta viruses despite vaccination had low Ct
 243 values consistent with the potential to shed infectious virus. Our findings support the notion that persons infected
 244 despite vaccination can transmit SARS-CoV-2. Therefore, preventing infection is critical to preventing trans-
 245 mission. Vaccinated and unvaccinated persons should be tested when symptomatic or after close contact with
 246 someone with suspected or confirmed COVID-19. Continued adherence to non-pharmaceutical interventions
 247 during periods of high community transmission to mitigate spread of COVID-19 remains important for both vac-
 248 cinated and unvaccinated individuals.

249
 250
 251

252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282

Figure 1




Figure 1. Individuals infected with SARS-CoV-2 despite full vaccination have low Ct values and shed similar amounts of infectious virus as unvaccinated individuals. A. N1 Ct values for SARS-CoV-2-positive specimens were grouped by vaccination status. RT-PCR was performed by Exact Sciences Corporation, responsible for over 10% of all PCR tests in Wisconsin during this period, using a qualitative diagnostic assay targeting the SARS-CoV-2 N gene (oligonucleotides identical to CDC's N1 primer and probe set) that has been authorized for emergency use by FDA (<https://www.fda.gov/media/138328/download>). See also **Table 1**. An effect size of $d < 0.2$ is negligible. The number of samples in each group is listed under the dot plot. **B.** N1 Ct values for SARS-CoV-2-positive specimens grouped by vaccination status for individuals who were symptomatic or either asymptomatic or did not have any information, at the time of testing. Light yellow box indicates Ct values < 25 . **C.** We

292 performed plaque assays on Vero E6 TMPRSS2 cells on a subset of specimens. Specimens were selected by
293 N1 Ct-matching between fully vaccinated and unvaccinated persons. Specimens from individuals with unknown
294 vaccination status were excluded from the analysis. Infectious titers are expressed as plaque-forming units
295 (PFU) per milliliter of specimen. Specimens underwent a freeze-thaw cycle prior to virus titration.

296

Supplemental materials

Supplemental Table 1: Comparisons between vaccine type

	Mean	95% CI	p-value [‡]	p-value ¹	p-value ²	p-value ³	p-value ⁴	p-value ⁵	p-value ⁶
Unvaccinated	22.9	22.8-23.0	<0.0001	<0.0001	0.0052	<0.0001	0.0064	0.9870	0.0001
Janssen	21.9	21.6-22.2							
Moderna	22.5	22.3-22.7							
Pfizer	22.0	21.8-22.1							

‡ comparisons between all groups

¹: comparison Unvaccinated vs. Janssen (adjusted for multiple comparisons using Tukey's HSD method)

²: comparison Unvaccinated vs. Moderna (adjusted for multiple comparisons using Tukey's HSD method)

³: comparison Unvaccinated vs. Pfizer (adjusted for multiple comparisons using Tukey's HSD method)

⁴: comparison Janssen vs. Moderna (adjusted for multiple comparisons using Tukey's HSD method)

⁵: comparison Janssen vs. Pfizer (adjusted for multiple comparisons using Tukey's HSD method)

⁶: comparison Moderna vs. Pfizer (adjusted for multiple comparisons using Tukey's HSD method)


Supplemental Table 2: Comparison of Ct values in vaccinated and unvaccinated persons, stratified by age group (there is a significant interaction between age group and vaccination status, $p < 0.0001$)

	Not Vaccinated		Vaccinated		Effect size d	p-value
	Mean	95% CI	Mean	95% CI		
0-11 yr	23.9	23.7-24.1	19.8	16.5-23.8	0.79	0.0466
12-18 yr	23.0	22.8-23.3	23.9	22.5-23.5	0.00	0.9242
19-35 yr	22.4	22.2-22.6	23.0	22.1-22.6	0.00	0.8846
36-60 yr	22.3	22.1-22.5	21.9	21.8-22.1	0.07	0.0080
>61 yr	22.3	21.9-22.8	22.1	21.8-22.3	0.05	0.3239

Supplemental Table 3: Comparison of Ct values in vaccinated and unvaccinated persons, stratified by sex.

	Unvaccinated		Vaccinated		Effect size d	p-value
	Mean	95% CI	Mean	95% CI		
Female	23.0	22.9-23.2	22.3	22.1-22.4	0.14	<0.0001
Male	22.8	22.6-22.9	22.0	21.8-22.1	0.15	<0.0001


Supplemental Figure 1



Supplemental Figure 1. Concordance between self-reported vaccination status and records in public health vaccine registries. Individuals were considered fully vaccinated based on vaccine registry (WIR/WEDSS) data if the registries indicated receipt of a final vaccine dose at least 14 days prior to submitting the sample used in our analysis. For individuals whose vaccination status could not be verified in the registry, self-reported data collected at the time of testing were used. Individuals were considered unvaccinated based on self-report only if there was an explicit declaration of unvaccinated status in the self-reported data. Individuals were considered fully vaccinated based on self-report if they fulfilled all of the following criteria: (1) indicated that they had received a COVID vaccine prior to testing; (2) indicated that they did not require another vaccine dose; and (3) reported a date of last vaccine dose that was at least 14 days prior to testing.


Specimens lacking data on vaccination status were excluded from the study. Specimens from partially vaccinated individuals (incomplete vaccine series, or <14 days post-final dose) were also excluded. Specimens from individuals who received a booster prior to sample collection were also excluded as non-equivalent to those fulfilling the criteria to be considered fully vaccinated. **A.** Of 20,431 specimens with vaccination status available from at least one source, 5,078 specimens had data available from both sources. Under-reporting of full vaccination status in self-reports 1,064/6,142 or 17%) was more common than over-reporting (409/5,487 or 7.4%). **B.** N1 Ct values for SARS-CoV-2-positive specimens grouped by vaccination status for individuals whose vaccination status was determined by vaccine registry or by self-reported data.

Supplemental Figure 2




Supplemental Figure 2. Log transformation of raw Ct values results in normally distributed residuals. Raw Ct values were not normally distributed, so we log-transformed all Ct values prior to ANOVA, and confirmed normality by plotting residuals and normal probability.

Supplemental Figure 3




Supplemental Figure 3. Density distributions of unvaccinated and vaccinated specimen collection dates by day since symptom onset. Day 0 on the x-axis denotes self-reported day of symptom onset. Negative values for days indicate specimen collection prior to symptom onset. Symptom onset data were available for n=6,871 unvaccinated cases and n=5,522 vaccinated cases. Two-sided K-S test: p=0.0012; median days since symptom onset were 2.4 for both unvaccinated and vaccinated cases.

Supplemental Figure 4



Supplemental Figure 4. Infectious SARS-CoV-2 detected in the majority of fully vaccinated individuals with low Ct values. Infectiousness was determined for a subset of N1 Ct-matched specimens with Ct <25 by inoculation onto Vero E6 TMPRSS2 cells, then determining presence or absence of cytopathic effects (CPE) after 5 days in culture. Specimens with unknown vaccination status were excluded from the analysis. Circles indicate presence of CPE; 'X' indicates no CPE detected.

Supplemental Figure 5



Supplemental Figure 5. Ct values do not differ substantially by vaccine type. **A.** Comparison of mean N1 Ct values in all specimens, stratified by vaccine type shows negligible effect ($d < 0.2$) of vaccine type on Ct value at time of positive test, relative to unvaccinated persons. **B.** The time analysis showed a decrease in N1 Ct values with time over 7 months. Combining all three vaccines, there was a significant decrease over the first 7 months, with a slope of -0.18 (95% CI: -0.26 - 0.10), p value < 0.0001. Individually, Janssen had a slope -0.19 (95% CI: -0.38 to -0.001, p-value=0.060), Moderna had a slope of -0.13 (95% CI: -0.28 - 0.02, p-value=0.092), Pfizer had a slope of -0.24 (95% CI: -0.24 to -0.13, p-value<0.0001).

468 **Conflict of interest**

469 The authors declare no conflicting interests.

470 **Ethics statement**

471 The University of Wisconsin-Madison Institutional Review Board deemed that this project qualifies as public
472 health surveillance activities as defined in the Common Rule, 45 CFR 46.102(l)(2). As such, the project is not
473 deemed to be research regulated under the Common Rule and therefore, does not require University of Wiscon-
474 sin-Madison IRB review and oversight.

475

476 The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Cen-
477 ters for Disease Control and Prevention or the institutions with which the authors are affiliated.

478 **Data availability**

479 Data and processing workflows are available at <https://go.wisc.edu/p22116>. To protect potentially personally
480 identifiable information, the publicly available dataset contains only PCR Ct values, vaccine status, age, sex,
481 manufacturer, symptom status, virus culture status, and days from symptom onset to testing for each specimen.

References

1. Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021. *Morbidity and Mortality Weekly Report*. 2021;70: 858–864.
2. Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, et al. The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach. *PLoS One*. 2021;16: e0254456.
3. Borchering RK, Viboud C, Howerton E, Smith CP, Truelove S, Runge MC, et al. Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States, April-September 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70: 719–724.
4. Shitrit P, Zuckerman NS, Mor O, Gottesman B-S, Chowers M. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. *Euro Surveill*. 2021;26. doi:10.2807/1560-7917.ES.2021.26.39.2100822
5. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. *N Engl J Med*. 2022;386: 744–756.
6. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer; 2016.
7. Zupin L, Fontana F, Clemente L, Ruscio M, Crovella S. Comparison between nucleic acid amplification tests, antigen immunofluorescence assay, and in vitro infectivity in SARS-CoV-2 diagnosis. *Braz J Microbiol*. 2022. doi:10.1007/s42770-022-00758-6
8. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020. doi:10.1056/NEJMoa2008457
9. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581: 465–469.
10. Oda G, Sharma A, Lucero-Obusan C, Schirmer P, Sohoni P, Holodniy M. COVID-19 Infections Among Healthcare Personnel in the United States Veterans Health Administration, March to August, 2020. *J Occup Environ Med*. 2021;63: 291–295.
11. Sharma A, Oda G, Holodniy M. COVID-19 vaccine breakthrough infections in Veterans Health Administration. *bioRxiv*. 2021. doi:10.1101/2021.09.23.21263864
12. Luring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ*. 2022;376: e069761.

13. Robles-Fontán MM, Nieves EG, Cardona-Gerena I, Irizarry RA. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico. *Lancet Reg Health Am.* 2022;9: 100212.
14. Terpos E, Karalis V, Ntanasis-Stathopoulos I, Evangelakou Z, Gavriatopoulou M, Manola MS, et al. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. *Biomedicines.* 2022;10. doi:10.3390/biomedicines10020338
15. Sughayer MA, Souan L, Abu Alhowr MM, Al Rimawi D, Siag M, Albadr S, et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies. *Vaccine.* 2022;40: 2841–2847.
16. Magalis BR, Mavian C, Tagliamonte M, Rich SN, Cash M, Riva A, et al. Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled-edged sword. *J Med Virol.* 2022. doi:10.1002/jmv.27726
17. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *N Engl J Med.* 2022;386: 933–941.
18. Bonnet B, Chabrolles H, Archimbaud C, Brebion A, Cosme J, Dutheil F, et al. Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. *Front Immunol.* 2022;13: 842912.
19. Burns MD, Boribong BP, Bartsch YC, Loiselle M, St Denis KJ, Sheehan ML, et al. Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children. *Vaccines (Basel).* 2022;10. doi:10.3390/vaccines10040492
20. Sanna G, Marongiu A, Firinu D, Piras C, Franci G, Galdiero M, et al. Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. *Vaccines (Basel).* 2022;10. doi:10.3390/vaccines10040531
21. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. *Lancet Respir Med.* 2022. doi:10.1016/S2213-2600(22)00101-1
22. Shapiro JR, Park H-S, Aytenfisu TY, Caputo C, Lee J, Johnston TS, et al. Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults. *medRxiv.* 2022. Available: <https://pubmed.ncbi.nlm.nih.gov/35607747>
23. Molani S, Hernandez PV, Roper RT, Duvvuri VR, Baumgartner AM, Goldman JD, et al. Risk factors for severe COVID-19 differ by age for hospitalized adults. *Sci Rep.* 2022;12: 6568.
24. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kocielek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to

- 547 Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr. 2020;174: 902–903.
- 548 25. Heald AH, Jenkins DA, Williams R, Sperrin M, Mudaliar RN, Syed A, et al. Mortality in People with Type 2
549 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. Diabetes
550 Ther. 2022;13: 1037–1051.
- 551 26. Chen U-I, Xu H, Krause TM, Greenberg R, Dong X, Jiang X. Factors Associated With COVID-19 Death in
552 the United States: Cohort Study. JMIR Public Health Surveill. 2022;8: e29343.
- 553 27. Euser S, Aronson S, Manders I, van Lelyveld S, Herpers B, Sinnige J, et al. SARS-CoV-2 viral-load distribu-
554 tion reveals that viral loads increase with age: a retrospective cross-sectional cohort study. Int J Epidemiol.
555 2022;50: 1795–1803.
- 556 28. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and
557 correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro
558 Surveill. 2020;25. doi:10.2807/1560-7917.ES.2020.25.32.2001483
- 559 29. Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, Hofmann J, et al. An analysis of SARS-CoV-2 viral
560 load by patient age. bioRxiv. medRxiv; 2020. doi:10.1101/2020.06.08.20125484
- 561 30. Maltezou HC, Magaziotou I, Dedoukou X, Eleftheriou E, Raftopoulos V, Michos A, et al. Children and Ado-
562 lescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads. Pediatr Infect Dis J.
563 2020;39: e388–e392.
- 564 31. Mahallawi WH, Alsamiri AD, Dabbour AF, Alsaeedi H, Al-Zalabani AH. Association of Viral Load in SARS-
565 CoV-2 Patients With Age and Gender. Front Med. 2021;8: 608215.
- 566 32. Penney J, Jung A, Koethe B, Doron S. Cycle threshold values and SARS-CoV-2: Relationship to demo-
567 graphic characteristics and disease severity. J Med Virol. 2022. doi:10.1002/jmv.27752
- 568 33. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic Features of Severe
569 Acute Respiratory Syndrome Coronavirus 2 Infection in Children. J Infect Dis. 2021;224: 1821–1829.
- 570 34. Lieberman NAP, Peddu V, Xie H, Shrestha L, Huang M-L, Mears MC, et al. In vivo antiviral host transcrip-
571 tional response to SARS-CoV-2 by viral load, sex, and age. PLoS Biol. 2020;18: e3000849.
- 572 35. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase
573 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384: 1824–1835.
- 574 36. Sa S, Lee CW, Shim SR, Yoo H, Choi J, Kim JH, et al. The Safety of mRNA-1273, BNT162b2 and JNJ-
575 78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data. Vaccines
576 (Basel). 2022;10. doi:10.3390/vaccines10020320
- 577 37. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness
578 of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and me-

579 ta-regression. Lancet. 2022;399: 924–944.

580 38. Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine
581 against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383: 1920–1931.

582 39. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis
583 of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; eab3435.

584 40. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of
585 Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383: 2439–2450.

586 41. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Effect of Delta variant on
587 viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27:
588 2127–2135.

589 42. Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological and serological kinetics of
590 SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect.
591 2022;28: 612.e1–612.e7.

592 43. Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, et al. Duration of viral shedding and culture
593 positivity with postvaccination SARS-CoV-2 delta variant infections. JCI Insight. 2022;7. doi:10.1172/jci.
594 insight.155483

595 44. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in
596 Vaccinated Health Care Workers. N Engl J Med. 2021;385: 1474–1484.

597 45. SriramanAK, ShaikhA, VaswaniS, MestryT, PatelG, SakthivelS, et al. Impact of Delta and Vaccination on SARS-
598 CoV- transmission risk: Lessons for Emerging Breakthrough infections. doi:10.1101/2022.03.02.22271385



599 46. Kislaya I, Peralta-Santos A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative complete scheme
600 and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2
601 Omicron (BA.1) and Delta (B.1.617.2) variants. bioRxiv. 2022. doi:10.1101/2022.01.31.22270200

602 47. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral Dynamics of SARS-CoV-2 Vari-
603 ants in Vaccinated and Unvaccinated Persons. N Engl J Med. 2021;385: 2489–2491.

604 48. Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-
605 CoV-2 infection reveals substantial heterogeneity in infectiousness. Nature Microbiology. 2022; 1–13.

A

All Cases

**C****B**